In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Health technology is changing the way we treat pain. Orthokine Therapy uses the body’s own healing proteins to reduce ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...